Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Biomarkers for monitoring pre-analytical quality variation of mRNA in blood samples

H. Zhang, V. Korenková, R. Sjöback, D. Švec, J. Björkman, M. Kruhøffer, P. Verderio, S. Pizzamiglio, CM. Ciniselli, R. Wyrich, U. Oelmueller, M. Kubista, T. Lindahl, A. Lönneborg, E. Rian,

. 2014 ; 9 (11) : e111644.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, validační studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc15022941

There is an increasing need for proper quality control tools in the pre-analytical phase of the molecular diagnostic workflow. The aim of the present study was to identify biomarkers for monitoring pre-analytical mRNA quality variations in two different types of blood collection tubes, K2EDTA (EDTA) tubes and PAXgene Blood RNA Tubes (PAXgene tubes). These tubes are extensively used both in the diagnostic setting as well as for research biobank samples. Blood specimens collected in the two different blood collection tubes were stored for varying times at different temperatures, and microarray analysis was performed on resultant extracted RNA. A large set of potential mRNA quality biomarkers for monitoring post-phlebotomy gene expression changes and mRNA degradation in blood was identified. qPCR assays for the potential biomarkers and a set of relevant reference genes were generated and used to pre-validate a sub-set of the selected biomarkers. The assay precision of the potential qPCR based biomarkers was determined, and a final validation of the selected quality biomarkers using the developed qPCR assays and blood samples from 60 healthy additional subjects was performed. In total, four mRNA quality biomarkers (USP32, LMNA, FOSB, TNRFSF10C) were successfully validated. We suggest here the use of these blood mRNA quality biomarkers for validating an experimental pre-analytical workflow. These biomarkers were further evaluated in the 2nd ring trial of the SPIDIA-RNA Program which demonstrated that these biomarkers can be used as quality control tools for mRNA analyses from blood samples.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15022941
003      
CZ-PrNML
005      
20150709122647.0
007      
ta
008      
150709s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0111644 $2 doi
035    __
$a (PubMed)25369468
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zhang, Hui $u DiaGenic ASA, Oslo, Norway.
245    10
$a Biomarkers for monitoring pre-analytical quality variation of mRNA in blood samples / $c H. Zhang, V. Korenková, R. Sjöback, D. Švec, J. Björkman, M. Kruhøffer, P. Verderio, S. Pizzamiglio, CM. Ciniselli, R. Wyrich, U. Oelmueller, M. Kubista, T. Lindahl, A. Lönneborg, E. Rian,
520    9_
$a There is an increasing need for proper quality control tools in the pre-analytical phase of the molecular diagnostic workflow. The aim of the present study was to identify biomarkers for monitoring pre-analytical mRNA quality variations in two different types of blood collection tubes, K2EDTA (EDTA) tubes and PAXgene Blood RNA Tubes (PAXgene tubes). These tubes are extensively used both in the diagnostic setting as well as for research biobank samples. Blood specimens collected in the two different blood collection tubes were stored for varying times at different temperatures, and microarray analysis was performed on resultant extracted RNA. A large set of potential mRNA quality biomarkers for monitoring post-phlebotomy gene expression changes and mRNA degradation in blood was identified. qPCR assays for the potential biomarkers and a set of relevant reference genes were generated and used to pre-validate a sub-set of the selected biomarkers. The assay precision of the potential qPCR based biomarkers was determined, and a final validation of the selected quality biomarkers using the developed qPCR assays and blood samples from 60 healthy additional subjects was performed. In total, four mRNA quality biomarkers (USP32, LMNA, FOSB, TNRFSF10C) were successfully validated. We suggest here the use of these blood mRNA quality biomarkers for validating an experimental pre-analytical workflow. These biomarkers were further evaluated in the 2nd ring trial of the SPIDIA-RNA Program which demonstrated that these biomarkers can be used as quality control tools for mRNA analyses from blood samples.
650    _2
$a odběr vzorku krve $7 D001800
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a lidé $7 D006801
650    _2
$a sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů $7 D020411
650    _2
$a polymerázová řetězová reakce $7 D016133
650    _2
$a stabilita RNA $7 D020871
650    _2
$a messenger RNA $x krev $x chemie $x genetika $x izolace a purifikace $7 D012333
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a validační studie $7 D023361
700    1_
$a Korenková, Vlasta $u Laboratory of Gene Expression, Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Sjöback, Robert $u TATAA Biocenter, Gothenburg, Sweden.
700    1_
$a Švec, David $u Laboratory of Gene Expression, Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic; TATAA Biocenter, Gothenburg, Sweden.
700    1_
$a Björkman, Jens $u TATAA Biocenter, Gothenburg, Sweden.
700    1_
$a Kruhøffer, Mogens $u AROS Applied Biotechnology AS, Aarhus, Denmark.
700    1_
$a Verderio, Paolo $u Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.
700    1_
$a Pizzamiglio, Sara $u Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.
700    1_
$a Ciniselli, Chiara Maura $u Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.
700    1_
$a Wyrich, Ralf $u Qiagen GmbH, Hilden, Germany.
700    1_
$a Oelmueller, Uwe $u Qiagen GmbH, Hilden, Germany.
700    1_
$a Kubista, Mikael $u Laboratory of Gene Expression, Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic; TATAA Biocenter, Gothenburg, Sweden.
700    1_
$a Lindahl, Torbjørn $u DiaGenic ASA, Oslo, Norway.
700    1_
$a Lönneborg, Anders $u DiaGenic ASA, Oslo, Norway.
700    1_
$a Rian, Edith $u DiaGenic ASA, Oslo, Norway.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 11 (2014), s. e111644
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25369468 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150709122707 $b ABA008
999    __
$a ok $b bmc $g 1083280 $s 905934
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 9 $c 11 $d e111644 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20150709

Najít záznam

Citační ukazatele

Možnosti archivace